Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Catheter Precision's 3-Year RORE % for the quarter that ended in Mar. 2026 was 44.25%.
The industry rank for Catheter Precision's 3-Year RORE % or its related term are showing as below:
FRA:4RM's 3-Year RORE % is ranked better than 84.3% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.03
vs FRA:4RM: 44.25
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Catheter Precision 3-Year RORE % Related Terms
Catheter Precision 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Catheter Precision's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4RM vs ALURD, BJDX, AMIX: 3-Year RORE % Comparison
For the Medical Devices subindustry, Catheter Precision's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catheter Precision 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Catheter Precision's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Catheter Precision's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Catheter Precision (FRA:4RM) has a 3-Year RORE % of 44.25 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Catheter Precision and its competitors. According to the industry distribution chart, Catheter Precision ranks #122 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 15.7%.
Is Catheter Precision's 3-Year RORE % too high?
Catheter Precision's current 3-Year RORE % is 44.25. Based on the distribution chart, Catheter Precision ranks #122 out of 777 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Catheter Precision has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Catheter Precision's 3-Year RORE % compare to ALURD and BJDX?
According to the Medical Devices & Instruments industry distribution chart, Catheter Precision ranks #122 out of 777 companies for 3-Year RORE %. This places Catheter Precision in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Catheter Precision and its competitors. Catheter Precision's current 3-Year RORE % is 44.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catheter Precision stock overvalued right now?
Catheter Precision (FRA:4RM) has a current 3-Year RORE % of 44.25. The stock's GF Value™ is €218.38, compared to a current price of €100.89 — trading 53.8% below its estimated fair value. The current 3-Year RORE % is 44.25. Catheter Precision's overall GF Score™ is 23/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Catheter Precision (FRA:4RM), the current 3-Year RORE % is 44.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catheter Precision (FRA:4RM) Overvalued in 2026?
Based on GuruFocus' analysis, Catheter Precision stock appears to be undervalued.
The current stock price of €100.89 is trading 53.8% below its estimated GF Value™ of €218.38.
Key valuation signals for FRA:4RM:
3-Year RORE %: 44.25
GF Value™: €218.38 vs. price of €100.89 (53.8% below fair value)
No single metric tells the full story. See the FRA:4RM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catheter Precision Inc is engaged in the design, manufacture, and sale of medical technologies focused in the field of cardiac electrophysiology, or EP. The company's two primary products include the VIVO System and LockeT. The VIVO System, which is an acronym for View into Ventricular Onset System(VIVO or VIVO System), is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its newest product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure.
23GF Score
Get the complete analysis for FRA:4RM
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4RM has been successfully added to your 
